Clinical Scenario 2: Older Patient with EGFR-Mutant NSCLC and Multiple Comorbidities

A 72-year-old patient presents with multiple baseline challenges: mild hypertension, stage 2 chronic kidney disease, hearing loss, and 3 small brain metastases planned for stereotactic radiosurgery. Additional concerning features include borderline ECOG performance status, creatinine clearance of 55, baseline neutrophil count of 1.9, and geographic barriers with 90-minute drives to the infusion center with an elderly spouse as caregiver.

Molecular profiling reveals EGFR L858R mutation with concurrent TP53 Y220C mutation, creating high-risk disease characteristics mandating combination consideration despite patient limitations.

Dr. Rodriguez emphasizes that poor-risk disease features (TP53 and L858R mutations) support combination therapy, whereas patient characteristics suggest chemotherapy tolerability concerns. Baseline renal insufficiency, hearing loss, and neutropenia risk favor avoiding chemotherapy-associated toxicities in favor of regimens without these specific risks.

The MARIPOSA regimen offers advantages for this patient population: avoiding chemotherapy-related toxicities while providing excellent CNS activity. MARIPOSA data demonstrate remarkable brain metastases outcomes with 35-month duration of response compared to historical 3- to 4-month survivals for untreated brain metastases.

Geographic considerations favor monthly subcutaneous visits over 3-weekly chemotherapy infusions, reducing caregiver burden and infusion center time. The convenience factor becomes particularly important for elderly patients with transportation limitations.

Dr. Olazagasti suggests delaying stereotactic radiosurgery given both regimens' demonstrated CNS efficacy. Recent ASCO 2026 data showing no overall survival advantage for early versus delayed radiation supports avoiding radiation-associated cognitive effects in elderly patients when systemic therapies provide excellent CNS control.